Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.62 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.51 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.51 |
| ▸ | BTK | Q06187 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | GCK | P35557 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17455067 | 0.94 | GPR119 (0.62) | GPR119NAMPTPDK4HTR6GRM5 | |
| SCHEMBL1655856 | 0.84 | GPR119 (0.71) | GPR119 | |
| SCHEMBL22324996 | 0.83 | NAMPT (0.55) | GPR119NAMPTPDK4HTR6GRM5 | |
| SCHEMBL8193684 | 0.82 | NAMPT (0.59) | GPR119NAMPTPDK4TNK2BTK | |
| SCHEMBL19434391 | 0.82 | GPR119 (0.57) | GPR119NAMPTPDK4TNK2HTR6 | |
| SCHEMBL29071744 | 0.82 | NAMPT (0.57) | GPR119NAMPTPDK4HTR6GRM5 | |
| SCHEMBL27141544 | 0.81 | GPR119 (0.54) | GPR119NAMPTPDK4HTR6GRM5 | |
| SCHEMBL22324776 | 0.81 | HTR6 (0.55) | GPR119NAMPTPDK4HTR6GRM5 | |
| SCHEMBL8912847 | 0.81 | NAMPT (0.63) | GPR119NAMPTPDK4TNK2HTR6 | |
| SCHEMBL1578063 | 0.80 | GPR119 (0.64) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010048149-A2 | HETEROCYCLIC MODULATORS OF GPR119 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-04-29 | — | — | WO | disclosed |